In terms of treatment preferences (Table 4), oral phosphodiesterase-4 (PDE-4) inhibitors were more commonly used in the South zone as a first-line treatment for mild AD (28.9%) than in the other zones, where TCS and TCIs remained the primary choices. This evidence concerns the gene PDE4A and Alzheimer disease.